CDK4 binding peptide
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsBruce M. Paterson, Jian-Min Zhang
Life of this patent
Estimating the term…
Abstract
The invention provides a CDK4 binding peptide, and a nucleic acid sequence coding therefore, that is capable of specifically binding cyclin dependent kinase (CDK4) to inhibit CDK4 activity and cell growth. The invention also includes variants of the CDK4 binding peptide which comprise polypeptides which have at least about 80% amino acid sequence identity with the amino acid sequence of the CDK4 binding peptide. In another embodiment, the invention provides chimeric molecules comprising a CDK4 binding peptide fused to a heterologous peptide or amino acid sequence, preferably a nuclear localization signal. Therapeutic and diagnostic methods are also provided.
Claims5
An isolated peptide comprising:
- Tyr-Ser-Gly-Pro-Pro-Ser-Gly-Ala-Arg-Arg-Arg-Asn-Cys-Tyr-Glu (SEQ ID NO:1);
- wherein the isolated peptide does not include a basic helix-loop-helix (bHLH) domain;
- wherein the isolated peptide binds cyclin dependent kinase 4.
A fusion protein comprising:
- (a) a peptide comprising Tyr-Ser-Gly-Pro-Pro-Ser-Gly-Ala-Arg-Arg-Arg-Asn-Cys-Tyr-Glu (SEQ ID NO:1), wherein the peptide binds cyclin dependent kinase 4;
- and
- (b) a heterologous amino acid sequence.
A method of inhibiting the activity of CDK4 comprising:
- contacting CDK4 with a CDK4 binding peptide comprising:
- Tyr-Ser-Gly-Pro-Ser-Gly-Ala-Arg-Arg-Asn-Cys-Tyr-Glu (SEQ ID NO:1), wherein the peptide does not include a basic helix-loop-helix domain in an amount effective to inhibit the activity of CDK4.
Dependencies are inferred from the claim text.